Novo Nordisk is going all in on Ozempic, its once-weekly GLP-1 injection for diabetes that was approved by the FDA in December 2017. The Danish pharma has shifted marketing spend away from Victoza, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results